TRAVERE THERAPEUTICS, INC. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 28 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $130M | ↑+73.4% | — | — | — |
| 2025-09-30 | $165M | ↑+162.1% | $26M | ↑+146.9% | 15.1% |
| 2025-06-30 | $114M | ↑+111.5% | $-13M | ↑+81.9% | -11.1% |
| 2025-03-31 | $82M | ↑+97.5% | $-41M | ↑+69.7% | -52.2% |
| 2024-12-31 | $75M | ↑+66.0% | — | — | — |
| 2024-09-30 | $63M | ↑+69.6% | $-55M | ↓-136.4% | -89.3% |
| 2024-06-30 | $54M | ↑+68.1% | $-70M | ↑+17.8% | -125.1% |
| 2024-03-31 | $41M | ↑+33.9% | $-136M | ↓-57.6% | -336.5% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$130M
↑+73.4% +$55M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
TVTX Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyTVTX Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics